CN106117309B - 丙型肝炎病毒的抑制剂 - Google Patents

丙型肝炎病毒的抑制剂 Download PDF

Info

Publication number
CN106117309B
CN106117309B CN201610474633.5A CN201610474633A CN106117309B CN 106117309 B CN106117309 B CN 106117309B CN 201610474633 A CN201610474633 A CN 201610474633A CN 106117309 B CN106117309 B CN 106117309B
Authority
CN
China
Prior art keywords
alkyl
group
optionally substituted
carbocylic radical
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610474633.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106117309A (zh
Inventor
凯拉·比昂逊
埃达·卡纳莱斯
杰里米·J.·科特雷耳
卡皮尔·库马尔·卡尔基
艾希莉·安妮·卡塔娜
达瑞尔·加藤
小林哲也
约翰·O.·林科
鲁本·马丁内斯
巴顿·W.·菲利普斯
边衡正
迈克尔·桑吉
亚当·詹姆斯·施里尔
达斯汀·西格尔
詹姆斯·G.·泰勒
晴·维特·德兰
马丁 特里萨·亚丽杭德拉·特雷霍
兰德尔·W.·维维安
杨正宇
杰夫·扎布洛基
希拉·茨普费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48803614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106117309(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Publication of CN106117309A publication Critical patent/CN106117309A/zh
Application granted granted Critical
Publication of CN106117309B publication Critical patent/CN106117309B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201610474633.5A 2012-07-03 2013-07-02 丙型肝炎病毒的抑制剂 Active CN106117309B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667806P 2012-07-03 2012-07-03
US61/667,806 2012-07-03
US201361798524P 2013-03-15 2013-03-15
US61/798,524 2013-03-15
CN201380042756.6A CN104540832B (zh) 2012-07-03 2013-07-02 丙型肝炎病毒的抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380042756.6A Division CN104540832B (zh) 2012-07-03 2013-07-02 丙型肝炎病毒的抑制剂

Publications (2)

Publication Number Publication Date
CN106117309A CN106117309A (zh) 2016-11-16
CN106117309B true CN106117309B (zh) 2019-08-30

Family

ID=48803614

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610474633.5A Active CN106117309B (zh) 2012-07-03 2013-07-02 丙型肝炎病毒的抑制剂
CN201380042756.6A Active CN104540832B (zh) 2012-07-03 2013-07-02 丙型肝炎病毒的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380042756.6A Active CN104540832B (zh) 2012-07-03 2013-07-02 丙型肝炎病毒的抑制剂

Country Status (40)

Country Link
US (7) US9296782B2 (enExample)
EP (4) EP3159345B1 (enExample)
JP (4) JP6025977B2 (enExample)
KR (3) KR101610575B1 (enExample)
CN (2) CN106117309B (enExample)
AP (1) AP3903A (enExample)
AR (1) AR091661A1 (enExample)
AU (6) AU2013286729B2 (enExample)
BR (2) BR122021012378B1 (enExample)
CA (1) CA2877005C (enExample)
CL (1) CL2014003634A1 (enExample)
CO (1) CO7160104A2 (enExample)
CR (1) CR20150045A (enExample)
CY (2) CY1118379T1 (enExample)
DK (2) DK2870160T3 (enExample)
EA (2) EA033961B1 (enExample)
EC (1) ECSP15002066A (enExample)
ES (3) ES2827300T3 (enExample)
HR (2) HRP20161379T1 (enExample)
HU (2) HUE042345T2 (enExample)
IL (4) IL236500B (enExample)
IN (1) IN2014MN02598A (enExample)
LT (2) LT2870160T (enExample)
MD (2) MD4602B1 (enExample)
ME (2) ME03362B (enExample)
MX (2) MX360597B (enExample)
MY (1) MY173342A (enExample)
NZ (2) NZ739248A (enExample)
PE (1) PE20150204A1 (enExample)
PH (3) PH12014502862B1 (enExample)
PL (2) PL2870160T3 (enExample)
PT (2) PT3159345T (enExample)
RS (2) RS55494B1 (enExample)
SG (3) SG11201408739VA (enExample)
SI (2) SI2870160T1 (enExample)
SM (3) SMT201900167T1 (enExample)
TW (1) TWI602822B (enExample)
UA (1) UA119315C2 (enExample)
UY (1) UY34888A (enExample)
WO (1) WO2014008285A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
JP6511432B2 (ja) * 2013-03-15 2019-05-15 ギリアード サイエンシーズ， インコーポレイテッド Ｃ型肝炎ウイルスの大環状二環式阻害剤
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
SG11201604482QA (en) * 2013-12-23 2016-07-28 Gilead Sciences Inc Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
PT3087086T (pt) 2013-12-23 2019-02-06 Gilead Pharmasset Llc Formas cristalinas de um tripéptido inibidor de hcv ns3 macrocíclico
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP6643735B2 (ja) * 2015-02-16 2020-02-12 セントラル硝子株式会社 含フッ素α−ケトカルボン酸エステル類の実用的な製造方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
JOP20190052A1 (ar) 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
EP3577100A4 (en) * 2017-02-01 2021-03-10 Abbvie Inc. ENZYMATIC PROCESS FOR THE PRODUCTION OF (±) -2- (DIFLUOROMETHYL) -1- (ALCOXYCARBONYL) -CYCLOPROPANECARBONIC ACID AND (±) -2- (VINYL) -1- (ALCOXYCARBONYLURE) -CYCLOPROPANEC
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159285A (zh) * 2008-07-22 2011-08-17 默沙东公司 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138567D1 (de) 2000-12-12 2009-06-10 Schering Corp Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ES2361011T3 (es) 2002-05-20 2011-06-13 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c.
ATE481106T1 (de) 2002-05-20 2010-10-15 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
DE602004023924D1 (en) 2003-04-18 2009-12-17 Enanta Pharm Inc Ease-hemmer
WO2004103996A1 (en) 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2007000584A (es) 2004-07-16 2007-06-25 Gilead Sciences Inc Compuestos antivirales.
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7470664B2 (en) * 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
NZ565059A (en) 2005-07-25 2011-08-26 Intermune Inc Novel macrocyclic inhibitors of hepatitus C virus replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
MX2008001588A (es) * 2005-08-01 2008-02-19 Merck & Co Inc Inhibidores de proteasa ns3 del vhc.
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
BRPI0617274A2 (pt) 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
EP2079480B1 (en) 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US20100099695A1 (en) 2006-10-27 2010-04-22 Liverton Nigel J HCV NS3 Protease Inhibitors
JP5352464B2 (ja) 2006-10-27 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
AP2009005053A0 (en) 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
MX2009013827A (es) 2007-06-29 2010-03-01 Gilead Sciences Inc Compuestos antivirales.
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
JP2010540549A (ja) 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての尿素含有ペプチド
EP2215076A4 (en) 2007-10-24 2012-05-02 Virobay Inc COMPOUNDS CAPABLE OF INHIBITING CATHEPSIN S PROTEASE AND HCV REPLICATION
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
CA2708042A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
WO2009082697A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CN102036966A (zh) 2008-01-24 2011-04-27 益安药业 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
US8003659B2 (en) 2008-02-04 2011-08-23 Indenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AU2009217551B2 (en) 2008-02-25 2014-07-31 Msd Italia S.R.L. Therapeutic compounds
WO2009114633A1 (en) 2008-03-12 2009-09-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
US8372802B2 (en) 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
CA2720729A1 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
KR101647520B1 (ko) 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
WO2010021717A2 (en) 2008-08-20 2010-02-25 Sequoia Pharmaceuticals, Inc. Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
EP2687526A1 (en) 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2358736A1 (en) 2008-10-15 2011-08-24 Intermune, Inc. Therapeutic antiviral peptides
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
CA2743912A1 (en) 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
EA022272B1 (ru) 2008-11-21 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция эффективного ингибитора всг для перорального введения
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
BRPI0922913A2 (pt) 2008-12-10 2015-08-18 Achillion Pharmaceuticals Inc Análogos cíclicos de peptídeo 4-amino-4-oxobutanoil inibidores de replicação viral
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100160403A1 (en) 2008-12-19 2010-06-24 Gilead Sciences, Inc. Hcv ns3 protease inhibitors
MX2011006764A (es) 2008-12-23 2011-08-03 Ortho Mcneil Janssen Pharm Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc.
WO2010132163A1 (en) 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
CA2763122A1 (en) 2009-05-22 2010-11-25 Sequoia Pharmaceuticals Inc. Bimacrocyclic hcv ns3 protease inhibitors
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
SG178043A1 (en) 2009-07-31 2012-03-29 Cadila Healthcare Ltd Substituted benzamide derivatives as glucokinase (gk) activators
AU2010286681A1 (en) 2009-08-27 2012-02-09 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
EP2483290A4 (en) 2009-09-28 2013-05-01 Intermune Inc CYCLIC PEPTIC INHIBITORS FOR REPLICATION OF HEPATITIS C VIRUS
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
BR112012022774A2 (pt) 2010-03-10 2017-09-12 Abbott Lab Composição sólida compreendendo primeira e segunda dispersões sólidas amorfas
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
JP2013528217A (ja) 2010-06-07 2013-07-08 アッヴィ・インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害薬
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US20120094897A1 (en) 2010-09-15 2012-04-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
PE20140015A1 (es) 2010-09-21 2014-02-16 Enanta Pharm Inc Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
BR112013010836A2 (pt) 2010-11-01 2019-09-24 Genoscience Pharma inibidores específicos de ns3 protease de hcv
BR112013010372A2 (pt) 2010-12-14 2016-07-05 Merck Sharp & Dohme composto, e, método para preparar um composto
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012166459A1 (en) 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012269643A1 (en) 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
BR112014003798A2 (pt) 2011-08-19 2017-03-01 Merck Sharp & Dohme método para fabricar um composto, e, composto
MX2014005210A (es) 2011-10-31 2014-08-22 Merck Sharp & Dohme Composiciones utiles para el tratamiento de enfermedades virales.
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
EP2802313A1 (en) 2012-01-12 2014-11-19 Boehringer Ingelheim International GmbH Stabilized pharmaceutical formulations of a potent hcv inhibitor
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ， インコーポレイテッド Ｃ型肝炎ウイルスの大環状二環式阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159285A (zh) * 2008-07-22 2011-08-17 默沙东公司 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors

Also Published As

Publication number Publication date
IL236500A0 (en) 2015-02-26
AP2014008166A0 (en) 2014-12-31
JP2015523365A (ja) 2015-08-13
CA2877005C (en) 2016-12-13
HK1209416A1 (en) 2016-04-01
DK2870160T3 (en) 2017-01-23
SMT201600470T1 (it) 2017-03-08
SMT201900167T1 (it) 2019-05-10
CA2877005A1 (en) 2014-01-09
LT2870160T (lt) 2016-12-12
SG10201702950TA (en) 2017-06-29
NZ739248A (en) 2019-05-31
AU2016200201A1 (en) 2016-02-04
US20140017198A1 (en) 2014-01-16
CO7160104A2 (es) 2015-01-15
NZ703064A (en) 2016-12-23
BR112014033080B1 (pt) 2022-03-29
EP3492464B1 (en) 2020-08-19
AU2019222909B2 (en) 2021-03-25
CN104540832B (zh) 2016-08-24
IL236500B (en) 2018-02-28
JP2016041743A (ja) 2016-03-31
HRP20190578T1 (hr) 2019-05-17
EA201790661A2 (ru) 2017-08-31
KR20160040743A (ko) 2016-04-14
SMT201600470B (it) 2017-03-08
KR20150034698A (ko) 2015-04-03
AR091661A1 (es) 2015-02-18
US10335409B2 (en) 2019-07-02
ES2716138T3 (es) 2019-06-10
PL3159345T3 (pl) 2019-09-30
CL2014003634A1 (es) 2015-11-06
RS58409B1 (sr) 2019-04-30
PH12014502862A1 (en) 2015-02-23
KR102040023B1 (ko) 2019-11-05
US20160130300A1 (en) 2016-05-12
IL252446A0 (en) 2017-07-31
RS55494B1 (sr) 2017-04-28
MX360597B (es) 2018-11-09
PH12020550552A1 (en) 2021-07-26
IL261581B (en) 2019-10-31
AP3903A (en) 2016-11-17
US20190008858A1 (en) 2019-01-10
PE20150204A1 (es) 2015-02-12
JP2020143107A (ja) 2020-09-10
BR122021012378B1 (pt) 2022-05-10
CY1121418T1 (el) 2020-05-29
IN2014MN02598A (enExample) 2015-07-24
EP3159345A1 (en) 2017-04-26
CR20150045A (es) 2015-05-13
EA033961B1 (ru) 2019-12-13
US20170290827A1 (en) 2017-10-12
AU2013286729B2 (en) 2015-11-12
HRP20161379T1 (hr) 2016-12-02
EA027390B1 (ru) 2017-07-31
DK3159345T3 (en) 2019-03-25
US9655944B2 (en) 2017-05-23
PT2870160T (pt) 2016-12-12
ME02547B (me) 2017-02-20
PL2870160T3 (pl) 2017-05-31
CY1118379T1 (el) 2017-06-28
AU2017203984A1 (en) 2017-07-06
MD20140136A2 (ro) 2015-05-31
HK1210151A1 (en) 2016-04-15
UA119315C2 (uk) 2019-06-10
US20190365748A1 (en) 2019-12-05
MY173342A (en) 2020-01-17
HUE042345T2 (hu) 2019-06-28
KR101610575B1 (ko) 2016-04-07
KR20190124346A (ko) 2019-11-04
EA201492214A1 (ru) 2015-10-30
TWI602822B (zh) 2017-10-21
SG10201912269YA (en) 2020-02-27
UY34888A (es) 2014-01-31
MX2018013668A (es) 2019-01-28
JP2018154651A (ja) 2018-10-04
EP2870160B1 (en) 2016-09-28
HUE032404T2 (en) 2017-09-28
AU2017203984B2 (en) 2019-06-06
CN106117309A (zh) 2016-11-16
PT3159345T (pt) 2019-04-15
US20150175655A1 (en) 2015-06-25
EP3492464A1 (en) 2019-06-05
ES2605383T3 (es) 2017-03-14
AU2016200670A1 (en) 2016-02-25
AU2013286729A1 (en) 2015-01-22
BR112014033080A2 (pt) 2017-06-27
EP3159345B1 (en) 2019-01-09
MD4602B1 (ro) 2018-11-30
EA201790661A3 (ru) 2017-10-31
MD20180040A2 (ro) 2018-11-30
US10603318B2 (en) 2020-03-31
ES2827300T3 (es) 2021-05-20
PH12014502862B1 (en) 2015-02-23
US20160361375A1 (en) 2016-12-15
US9296782B2 (en) 2016-03-29
EP2870160A1 (en) 2015-05-13
LT3159345T (lt) 2019-03-12
EP3825312A1 (en) 2021-05-26
SG11201408739VA (en) 2015-01-29
IL261581A (en) 2018-10-31
IL269662A (en) 2019-11-28
PH12016502040A1 (en) 2019-02-27
SI3159345T1 (sl) 2019-03-29
WO2014008285A1 (en) 2014-01-09
AU2019222909A1 (en) 2019-09-19
ECSP15002066A (es) 2015-11-30
CN104540832A (zh) 2015-04-22
ME03362B (me) 2019-10-20
SI2870160T1 (sl) 2016-11-30
JP6025977B2 (ja) 2016-11-16
TW201414740A (zh) 2014-04-16
MX2014015846A (es) 2015-08-14
AU2021204238A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
CN106117309B (zh) 丙型肝炎病毒的抑制剂
CN104662033A (zh) 黄病毒科病毒的大环抑制剂
HK1231100B (zh) 丙型肝炎病毒的抑制剂
HK1231100A (en) Inhibitors of hepatitis c virus
HK1231100A1 (en) Inhibitors of hepatitis c virus
HK1209416B (zh) 丙型肝炎病毒的抑制剂
HK1236517B (en) Inhibitors of hepatitis c virus
HK1236517A (en) Inhibitors of hepatitis c virus
HK1236517A1 (en) Inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231100

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190417

Address after: American California

Applicant after: Pharmasset Inc.

Address before: American California

Applicant before: Gilead Sciences Inc.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211201

Address after: California, USA

Patentee after: GILEAD SCIENCES, Inc.

Address before: California

Patentee before: GILEAD PHARMASSET LLC